4.3 Article

RUNX1 promote invasiveness in pancreatic ductal adenocarcinoma through regulating miR-93

Journal

ONCOTARGET
Volume 8, Issue 59, Pages 99567-99579

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.20433

Keywords

pancreatic ductal adenocarcinoma (PDAC); miR-93; RUNX1; HMGA2 (High mobility group AT-hook 2); tumor progression

Funding

  1. National Natural Science Foundations of China [81672648, 81472326, 81400664, 81341070, 81172334, 30973470]
  2. CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001]
  3. project of basic scientific research of Central Public Welfare Research of CAMS [2016ZX310176-4]
  4. Special Fund of CAMS Molecular Pathology Center

Ask authors/readers for more resources

Runt-related transcription factor 1(RUNX1), a key factor in hematopoiesis that mediates specification and homeostasis of hematopoietic stem and progenitor cells (HSPCs), is also overexpressed in several solid human cancers, and correlated with tumor progression. However, the expression and function of RUNX1 in pancreatic ductal adenocarcinoma were still unclear. Here, we show that RUNX1 is highly expressed in pancreatic adenocarcinoma tissues and knocking down of RUNX1 attenuated aggressiveness in pancreatic cell lines. Moreover, we found that RUNX1 could negatively regulate the expression of miR-93. Bioinformatics method showed that there are two binding sites in the the promotor region of miR-93 precursor and through ChIP-qPCR and firefly luciferase reporter assay, we vertified that these two binding sites each have transcriptive activity in one pancreatic cell lines. This result supported our presumption that RUNX1 regulate miR-93 through binding to the promotor region of miR-93. Besides, the expression and function of miR-93 is quite the opposite, miR-93 overexpression suppresses migration and invasiveness in pancreatic cell lines supporting that RUNX1 negatively regulated miR-93. Our findings provided evidence regarding the role of RUNX1 as an oncogene through the inhibition of miR-93. Targeting RUNX1 can be a potential therapeutic strategy in pancreatic cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available